NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics

LUND, Sweden and PALO ALTO, Calif., June 18, 2018 /PRNewswire/ — NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive’s NVP015 program….

Source: https://www.prnewswire.com/news-releases/neurovive-out-licenses-targeted-lhon-therapy-to-bridgebio-pharmas-new-subsidiary-fortify-therapeutics-300667278.html